329 related articles for article (PubMed ID: 11251000)
21. [Doxorubicin and paclitaxel vs. 5-fluorouracyl, doxorubicin and cyclophosphamid in the first line treatment of metastatic breast cancer].
Nagykálnai T
Magy Onkol; 2002; 46(2):192-3. PubMed ID: 12202899
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
[TBL] [Abstract][Full Text] [Related]
23. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial.
Del Mastro L; Levaggi A; Michelotti A; Cavazzini G; Adami F; Scotto T; Piras M; Danese S; Garrone O; Durando A; Accortanzo V; Bighin C; Miglietta L; Pastorino S; Pronzato P; Castiglione F; Landucci E; Conte P; Bruzzi P
Breast Cancer Res Treat; 2016 Jan; 155(1):117-26. PubMed ID: 26661403
[TBL] [Abstract][Full Text] [Related]
24. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
25. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
[TBL] [Abstract][Full Text] [Related]
26. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.
Namer M; Soler-Michel P; Turpin F; Chinet-Charrot P; de Gislain C; Pouillart P; Delozier T; Luporsi E; Etienne PL; Schraub S; Eymard JC; Serin D; Ganem G; Calais G; Maillart P; Colin P; Trillet-Lenoir V; Prevost G; Tigaud D; Clavère P; Marti P; Romieu G; Wendling JL
Eur J Cancer; 2001 Jun; 37(9):1132-40. PubMed ID: 11378344
[TBL] [Abstract][Full Text] [Related]
27. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand.
Bishop JF; Dewar J; Toner G; Tattersall MH; Olver I; Ackland S; Kennedy I; Goldstein D; Gurney H; Walpole E; Levi J; Stephenson J
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-5-S17-9. PubMed ID: 9374084
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.
Zielinski C; Beslija S; Mrsic-Krmpotic Z; Welnicka-Jaskiewicz M; Wiltschke C; Kahan Z; Grgic M; Tzekova V; Inbar M; Cervek J; Chernozemsky I; Szanto J; Spanik S; Wagnerova M; Ghilezan N; Pawlega J; Vrbanec D; Khamtsov D; Soldatenkova V; Brodowicz T
J Clin Oncol; 2005 Mar; 23(7):1401-8. PubMed ID: 15735116
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
30. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
32. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
[TBL] [Abstract][Full Text] [Related]
33. A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer.
Zhang XH; Hao S; Gao B; Tian WG; Jiang Y; Zhang S; Guo LJ; Luo DL
Oncotarget; 2016 Dec; 7(51):84533-84543. PubMed ID: 27811367
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Nicholson BP; Paul DM; Hande KR; Shyr Y; Meshad M; Cohen A; Johnson DH
Clin Breast Cancer; 2000 Jul; 1(2):136-43; discussion 144. PubMed ID: 11899652
[TBL] [Abstract][Full Text] [Related]
35. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
[TBL] [Abstract][Full Text] [Related]
36. Prospective randomized trial of paclitaxel alone versus 5-fluorouracil/doxorubicin/cyclophosphamide as induction therapy in patients with operable breast cancer.
Buzdar AU; Hortobagyi GN; Asmar L; Theriault RL; Rahman Z; McNeese M; Singletary S; Ames F
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-31-S17-34. PubMed ID: 9374089
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
[TBL] [Abstract][Full Text] [Related]
38. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
Arun BK; Dhinghra K; Valero V; Kau SW; Broglio K; Booser D; Guerra L; Yin G; Walters R; Sahin A; Ibrahim N; Buzdar AU; Frye D; Sneige N; Strom E; Ross M; Theriault RL; Vadhan-Raj S; Hortobagyi GN
Oncologist; 2011; 16(11):1527-34. PubMed ID: 22042783
[TBL] [Abstract][Full Text] [Related]
39. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
[TBL] [Abstract][Full Text] [Related]
40. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
Boér K; Láng I; Juhos E; Pintér T; Szántó J
Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
